GlassScriptPhysician profile
Richard H Tidwell
NPI 1346208725
$3,483.61
in general payments reported to CMS, 2019-2025
33 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $502 · 2021: $471 · 2022: $509 · 2023: $396 · 2024: $649 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $597.62 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $298.50 | 2019-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $210.25 | 2020-2025 | Rexulti |
| Amgen INC. | $207.13 | 2019-2025 | Otezla, Repatha, Repatha |
| Sunovion Pharmaceuticals INC. | $189.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $183.94 | 2019-2024 | Verquvo, Belsomra |
| Abbvie INC. | $178.40 | 2021-2024 | Linzess, Creon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.40 | 2020-2024 | Caplyta |
| Glaxosmithkline, LLC. | $159.96 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $159.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.53 | 2020-2022 | |
| Pfizer INC. | $117.89 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $114.66 | 2019-2022 | |
| Lilly USA, LLC | $66.55 | 2020-2025 | Jardiance, Mounjaro |
| Mylan Specialty L.P. | $65.56 | 2019-2024 | Yupelri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $63.96 | 2025 | Cobenfy |
| Novo Nordisk INC | $59.33 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $57.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.23 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.89 | 2020-2023 | Trintellix |
| Astellas Pharma US INC | $50.85 | 2020-2023 | Myrbetriq |
| Allergan, INC. | $45.77 | 2020 | |
| Corium, LLC | $39.76 | 2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $34.66 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $32.90 | 2022-2024 | |
| Viatris Specialty LLC | $24.60 | 2025 | Yupelri |
| Exact Sciences Corporation | $23.68 | 2024 | Cologuard Collection Kit |
| Medtronic, INC. | $21.11 | 2025 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.83 | 2022 | |
| Sumitomo Pharma America, INC. | $16.32 | 2023 | Gemtesa |
| Alk-Abello, INC | $15.30 | 2024 | Odactra, Ragwitek, Grastek |
| Eisai INC. | $15.16 | 2020 | |
| Biogen, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tidwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.